PT-141 (Bremelanotide) Dosing for Older Adults Aged 50-64

The Standard Dose Applies to Adults 50-64

Bremelanotide is dosed at 1.75 mg by subcutaneous injection regardless of age. The FDA prescribing information does not specify dose reductions for patients between 50 and 64 years old, and no age-stratified pharmacokinetic data suggest altered drug clearance in this range.

The drug acts on melanocortin-4 receptors (MC4R) in the central nervous system to increase sexual desire. It reaches peak plasma concentration within approximately one hour after subcutaneous injection. Renal and hepatic impairment studies did not show clinically meaningful differences in exposure for mild-to-moderate organ dysfunction, which is relevant because adults in their 50s and 60s more frequently present with early-stage kidney or liver changes [1].

A single autoinjector pen delivers the full 1.75 mg dose. No titration schedule exists. Patients either respond to the standard dose or they do not. In the RECONNECT trial, the 1.75 mg dose was selected over the 0.75 mg dose because the lower dose failed to separate from placebo on co-primary endpoints [1]. Starting at a lower dose is therefore not supported by the trial data, even in older patients concerned about tolerability.

RECONNECT Trial Data and What It Means for Older Adults

The RECONNECT trial (N=1,247) enrolled premenopausal women with HSDD and demonstrated statistically significant improvements in both the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) score and the number of satisfying sexual events compared with placebo [1]. The mean age of enrolled participants was approximately 39 years. Few participants older than 50 were included, since the indication specifies premenopausal women.

This enrollment gap matters. The trial provides limited direct evidence for the 50-64 age group. Clinicians prescribing bremelanotide off-label to perimenopausal or postmenopausal women, or to men with erectile dysfunction in this age range, are extrapolating from a younger study population. The Endocrine Society's clinical practice guidelines on testosterone therapy note that sexual dysfunction in older adults often has multifactorial causes, including declining sex hormones, vascular disease, and medication side effects, all of which require evaluation before adding a centrally acting agent like bremelanotide [2].

Dr. Anita Clayton, a principal investigator on multiple HSDD trials, has stated: "Bremelanotide works through a different mechanism than PDE5 inhibitors or hormonal therapies, which makes it a consideration when those treatments are inadequate or contraindicated." This pharmacologic distinction is especially relevant for older adults who may have already tried and failed first-line options.

The practical takeaway: the 1.75 mg dose is the only dose with efficacy data. Off-label use in patients 50-64 should follow the same dosing protocol while adding cardiovascular and polypharmacy screening steps described below.

Cardiovascular Screening Before Prescribing

Bremelanotide produces a transient increase in blood pressure. In clinical trials, systolic pressure rose an average of 6 mmHg and diastolic pressure rose 3 mmHg, with peak effect occurring 2 to 3 hours post-dose and resolving within 12 hours [1]. Heart rate increased by an average of 3 beats per minute.

For a 35-year-old with a baseline blood pressure of 110/70, a transient bump to 116/73 is clinically insignificant. For a 58-year-old with treated hypertension running 138/86 on two antihypertensives, that same 6/3 mmHg increase pushes readings into a range where cardiovascular event risk compounds, particularly during the sympathetic activation of sexual activity itself.

The American Heart Association's 2017 hypertension guidelines define stage 2 hypertension as 140/90 mmHg or higher [3]. Bremelanotide is contraindicated in patients with uncontrolled hypertension. Before prescribing to anyone in the 50-64 age group, clinicians should:

1. Obtain a resting blood pressure measurement on the day of or within one week of prescribing.
2. Review the patient's most recent lipid panel and fasting glucose, since metabolic syndrome prevalence exceeds 40% in U.S. adults over age 50 [4].
3. Assess for known coronary artery disease, prior cerebrovascular events, or peripheral arterial disease.
4. Screen for concurrent use of antihypertensives that could mask blood pressure changes or interact hemodynamically.

Patients with well-controlled hypertension on stable medication are not automatically excluded, but they require closer monitoring during the first few uses.

Polypharmacy Considerations in the 50-64 Age Group

Adults aged 50-64 take a median of 4 prescription medications, according to CDC/NCHS data [5]. Bremelanotide is metabolized minimally by cytochrome P450 enzymes and is primarily cleared by hydrolysis into amino acid fragments. This means classical drug-drug interactions via CYP pathways are unlikely.

The more clinically relevant interactions are pharmacodynamic. Bremelanotide slows gastric emptying. Oral medications taken around the same time, particularly narrow-therapeutic-index drugs, may experience delayed absorption. The FDA label specifically warns against concurrent use with orally administered medications that depend on threshold concentrations for efficacy or safety, such as certain antibiotics, antiepileptics, or antiarrhythmics [1].

Practical guidance: patients should take their regular oral medications at least 1 to 2 hours before or after the bremelanotide injection. Prescribers should review the patient's full medication list and flag any drug with a narrow therapeutic index.

Blood pressure medications present a second interaction layer. Beta-blockers, ACE inhibitors, ARBs, and calcium channel blockers may partially counteract the hypertensive effect of bremelanotide, or in some cases, the combination could produce unpredictable blood pressure fluctuations. No formal interaction studies have been conducted with specific antihypertensive classes and bremelanotide. Clinicians are working from pharmacologic first principles here, not from randomized data.

Alpha-blockers used for benign prostatic hyperplasia (tamsulosin, alfuzosin) carry a theoretical risk of additive hemodynamic effects. Men aged 50-64 using both an alpha-blocker and bremelanotide off-label for erectile dysfunction should monitor for orthostatic hypotension, especially during the first dose.

Perimenopause, Andropause, and Hormonal Context

Sexual desire disorders in the 50-64 age range rarely exist in a hormonal vacuum. Women in perimenopause experience declining estradiol and fluctuating progesterone, while testosterone also decreases gradually from peak levels in the mid-20s. Men in the same age window may have testosterone levels below 300 ng/dL, meeting criteria for hypogonadism per the American Urological Association [6].

Bremelanotide acts centrally on melanocortin receptors. It does not replace missing hormones. For women in late perimenopause with concurrent vasomotor symptoms, vaginal atrophy, and decreased desire, hormone therapy may address multiple symptoms simultaneously, while bremelanotide addresses only the desire component. The 2022 Menopause Society position statement endorses hormone therapy as first-line for menopausal symptom management in appropriate candidates [7].

A clinically sound approach for the 50-64 population: evaluate and optimize the hormonal milieu first. Check serum testosterone (free and total), estradiol, SHBG, and DHEA-S. If hormone deficiency is identified and treatable, address it. If desire remains low despite adequate hormonal status, bremelanotide becomes a rational second-line or adjunctive option.

Some patients will present with normal hormone panels and persistent low desire. Bremelanotide may be appropriate as a first-line agent in these cases, even within the 50-64 range, provided cardiovascular screening is completed.

Practical Injection Technique and Administration Tips

The Vyleesi autoinjector is designed for self-administration in the abdomen. Injection technique does not vary by age, but a few points are worth emphasizing for older adults:

Subcutaneous fat distribution changes with age. Abdominal adiposity tends to increase in the 50-64 range, which generally makes subcutaneous injection easier rather than harder. Patients with very low body fat should pinch a skin fold to avoid intramuscular injection, which could alter absorption kinetics.

Needle anxiety is not age-dependent but is worth screening for. The autoinjector uses a 26-gauge, 5/8-inch needle, which is the same gauge used in many insulin pens. Patients who have experience with injectable medications (insulin, enoxaparin, testosterone) will find the technique familiar.

Storage is straightforward: the autoinjector should be kept at room temperature (20-25°C) and protected from light. Each pen is single-use. Patients should not attempt to re-dose from a used pen even if they believe the full volume was not delivered.

Timing guidance: inject 45 minutes before anticipated sexual activity. The window of effect extends from roughly 30 minutes to several hours post-injection. Patients should not inject more than once in a 24-hour period, and the FDA recommends no more than 8 doses per calendar month.

Nausea Management: The Most Common Barrier to Continued Use

Nausea is the most frequently reported adverse effect of bremelanotide. In the RECONNECT trial, 40% of bremelanotide-treated patients experienced nausea compared with 1% in the placebo group [1]. The nausea is typically mild to moderate, peaks within 1 to 2 hours of injection, and resolves within several hours. Fewer than 2% of trial participants discontinued because of nausea.

For adults 50-64 who may be on gastroprotective medications or who have age-related decreases in gastric motility, nausea could be more pronounced. Practical mitigation strategies include:

• Having a small, bland meal 1 to 2 hours before injection rather than injecting on an empty stomach.
• Keeping ondansetron 4 mg ODT (orally disintegrating tablet) on hand for rescue use if nausea occurs.
• Injecting in a reclined or semi-reclined position and remaining still for 15 to 20 minutes post-injection.

Nausea tends to attenuate with repeated use. Patients who tolerate the first three to four doses generally report less nausea on subsequent administrations. Clinicians should counsel patients about this pattern at the time of prescribing to prevent premature discontinuation.

Off-Label Use in Men Aged 50-64 with Erectile Dysfunction

Bremelanotide is FDA-approved only for HSDD in premenopausal women. Its use in men is entirely off-label. Phase 2 trials in men with erectile dysfunction showed some improvement in erectile function scores, but the drug was not advanced through phase 3 for a male indication [8].

Men aged 50-64 represent a large population with erectile dysfunction. The Massachusetts Male Aging Study found that 52% of men aged 40-70 reported some degree of erectile dysfunction, with prevalence increasing with age [8]. First-line therapy remains PDE5 inhibitors (sildenafil, tadalafil). Bremelanotide occupies a narrow niche: men who fail or cannot tolerate PDE5 inhibitors, have contraindications to those drugs, or who have a primary desire component to their dysfunction rather than a purely vascular etiology.

Dosing in men follows the same 1.75 mg subcutaneous protocol. No male-specific dose adjustments exist in the published literature. The cardiovascular precautions described above apply equally, and arguably more urgently, given that coronary artery disease prevalence is higher in men than women in this age bracket.

The evidence base for this use is thin. Prescribers and patients should approach off-label bremelanotide in men as an empiric trial, with clear outcome expectations set at baseline and a defined reassessment point (typically after 4 to 6 uses).

Monitoring and Follow-Up Protocol

After initiating bremelanotide in a patient aged 50-64, schedule a follow-up visit or telehealth check-in at 4 to 6 weeks. Assess three domains:

Efficacy: Has the patient noticed a subjective increase in sexual desire? For women, the FSDS-DAO or a simplified patient-reported outcome can track change. For men, the International Index of Erectile Function (IIEF-5) provides a validated score.

Tolerability: Document nausea severity and duration, injection site reactions, and any new symptoms. Transient facial flushing and headache occur in 15-20% of users [1].

Cardiovascular parameters: Recheck blood pressure. If readings have increased by more than 10 mmHg systolic from baseline on non-dosing days, investigate whether bremelanotide is contributing or whether an independent change in cardiovascular status has occurred.

Skin hyperpigmentation is a known melanocortin-related effect. In RECONNECT, focal darkening of the gingiva, face, or breasts occurred in a small percentage of patients. The effect is typically reversible upon discontinuation but may take months to resolve. Patients with darker baseline skin tones should be counseled about this possibility at initiation, and clinicians should document any new pigmentary changes at each follow-up [1].

The FDA-recommended limit of 8 doses per month provides a built-in usage ceiling. Patients who find themselves consistently reaching that limit should be evaluated for whether a scheduled (rather than as-needed) therapy, such as daily low-dose tadalafil or hormone replacement, might better serve their needs.